Therapeutic equivalence studies still present problems to regulatory r
eviewers from many perspectives. This paper is intended to discuss som
e of these concerns from the statistical viewpoint. There are, however
, also some newer approaches which may be particularly useful for the
investigation of therapeutic equivalence. (C) 1998 John Wiley & Sons L
td.